Pacific Biosciences of California, Inc. (PACB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 5.60 |
| Open | 5.75 |
| Bid | 6.17 x 3000 |
| Ask | 6.18 x 1300 |
| Day's Range | 5.46 - 6.19 |
| 52 Week Range | 4.51 - 36.36 |
| Volume | |
| Avg. Volume | 6,463,388 |
| Market Cap | 1.361B |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.19 |
| Earnings Date | Apr 27, 2022 - May 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.80 |
- Insider Monkey
Masayoshi Son is Selling These 9 Stocks in 2022
In this article, we discuss the 9 stocks Masayoshi Son is selling in 2022. If you wish to skip our detailed analysis of Son’s stock picks and hedge fund history, go directly to Masayoshi Son is Selling These 4 Stocks in 2022. Masayoshi Son is the man behind SoftBank, an investment and telecommunications media giant […]
- Insider Monkey
Korean-Japanese Billionaire Masayoshi Son’s 2022 Portfolio: 10 Stocks to Watch
In this article, we discuss the 2022 portfolio of Korean-Japanese Billionaire Masayoshi Son and the 10 stocks to watch. If you want to skip our detailed analysis of Son’s stock picks and hedge fund history, go directly to Korean-Japanese Billionaire Masayoshi Son’s 2022 Portfolio: 5 Stocks to Watch. Masayoshi Son is the CEO, Chairman and […]
- GlobeNewswire
PacBio Collaborates with iLAC and Robotic Biology Institute to Develop Automated Workflows
Advanced Automation Aims to Optimize Service Lab Efficiency and Highly Reproducible Data Production from HiFi Long-Read SequencingMENLO PARK, Calif., TOKYO, May 09, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with genome analysis company iLAC, Inc. (iLAC) and Robotic Biology Institute, Inc. (RBI) to develop fully automated end-to-end workflows for PacBio’s Sequel II and Sequel IIe HiFi
